A Phase 2b, Double-Blind, Randomized, Placebo-Controlled Study of RVT-101 in Subjects With Dementia With Lewy Bodies (DLB)

Trial Profile

A Phase 2b, Double-Blind, Randomized, Placebo-Controlled Study of RVT-101 in Subjects With Dementia With Lewy Bodies (DLB)

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Mar 2018

At a glance

  • Drugs Intepirdine (Primary)
  • Indications Lewy body disease
  • Focus Registrational; Therapeutic Use
  • Acronyms HEADWAY; HEADWAY-DLB
  • Sponsors Axovant Sciences
  • Most Recent Events

    • 08 Jan 2018 Results presented in an Axovant Sciences media release.
    • 08 Jan 2018 According to a company media release, Axovant Sciences has decided to discontinue intepirdine program based on negative results from MINDSET, HEADWAY and Gait and Balance studies.
    • 08 Jan 2018 Primary endpoint (Change from baseline on Unified Parkinsons Disease Rating Scale-Part III (UPDRS-III)) has not been met, according to an Axovant Sciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top